PUBLIC COMPANY
save$ALDXAldeyra Therapeutics, Inc.
$ALDXLexington, MA, USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study in Subjects With Retinitis Pigmentosa
- phase3A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
- phase3A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- phase2A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
- phase3A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
- phase3A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- phase3The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
- phase3A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (2)
- Mar 27, 26grantBrady Todd C · President and CEO1,880,510 sh
- Mar 27, 26grantBrady Todd C · President and CEO632,318 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that